| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 232 | 2024 | 314 | 46.660 |
Why?
|
| Electrocardiography | 282 | 2023 | 571 | 46.600 |
Why?
|
| Stroke | 87 | 2024 | 552 | 17.570 |
Why?
|
| Risk Assessment | 137 | 2023 | 1329 | 15.890 |
Why?
|
| Risk Factors | 307 | 2024 | 3600 | 13.400 |
Why?
|
| Cardiovascular Diseases | 84 | 2023 | 1058 | 13.340 |
Why?
|
| Hypertrophy, Left Ventricular | 44 | 2023 | 111 | 13.310 |
Why?
|
| Atherosclerosis | 83 | 2024 | 730 | 10.830 |
Why?
|
| Heart Rate | 58 | 2022 | 316 | 10.340 |
Why?
|
| Heart Conduction System | 46 | 2023 | 71 | 10.140 |
Why?
|
| Heart Failure | 41 | 2023 | 576 | 10.050 |
Why?
|
| Middle Aged | 367 | 2023 | 10936 | 9.890 |
Why?
|
| Male | 445 | 2024 | 18012 | 9.790 |
Why?
|
| Female | 446 | 2024 | 18379 | 9.660 |
Why?
|
| Myocardial Infarction | 34 | 2023 | 424 | 9.650 |
Why?
|
| Arrhythmias, Cardiac | 40 | 2023 | 81 | 9.470 |
Why?
|
| Nutrition Surveys | 41 | 2023 | 137 | 9.410 |
Why?
|
| United States | 219 | 2023 | 3693 | 9.280 |
Why?
|
| Hypertension | 53 | 2023 | 918 | 9.110 |
Why?
|
| Humans | 531 | 2024 | 29556 | 8.870 |
Why?
|
| Aged | 296 | 2024 | 9590 | 8.700 |
Why?
|
| Incidence | 166 | 2023 | 1127 | 8.620 |
Why?
|
| European Continental Ancestry Group | 77 | 2020 | 1132 | 7.910 |
Why?
|
| African Americans | 73 | 2022 | 1375 | 6.740 |
Why?
|
| Heart Atria | 22 | 2023 | 62 | 6.510 |
Why?
|
| Follow-Up Studies | 120 | 2023 | 2124 | 6.250 |
Why?
|
| Death, Sudden, Cardiac | 29 | 2022 | 59 | 6.230 |
Why?
|
| Proportional Hazards Models | 87 | 2022 | 711 | 6.000 |
Why?
|
| Prospective Studies | 131 | 2023 | 2046 | 5.730 |
Why?
|
| Prognosis | 87 | 2021 | 1372 | 5.550 |
Why?
|
| Heart Diseases | 17 | 2024 | 99 | 5.200 |
Why?
|
| Long QT Syndrome | 19 | 2022 | 39 | 4.760 |
Why?
|
| Brain Ischemia | 19 | 2020 | 136 | 4.700 |
Why?
|
| Predictive Value of Tests | 59 | 2021 | 796 | 4.580 |
Why?
|
| Antihypertensive Agents | 24 | 2023 | 345 | 4.560 |
Why?
|
| Aged, 80 and over | 104 | 2024 | 3764 | 4.530 |
Why?
|
| Continental Population Groups | 20 | 2020 | 221 | 4.420 |
Why?
|
| Prevalence | 72 | 2021 | 910 | 4.300 |
Why?
|
| Ethnic Groups | 38 | 2020 | 440 | 4.210 |
Why?
|
| Coronary Artery Disease | 19 | 2023 | 377 | 4.010 |
Why?
|
| Cohort Studies | 94 | 2023 | 1701 | 3.660 |
Why?
|
| Atrial Premature Complexes | 13 | 2021 | 15 | 3.530 |
Why?
|
| Cause of Death | 28 | 2020 | 222 | 3.510 |
Why?
|
| Tobacco Smoke Pollution | 6 | 2022 | 37 | 3.510 |
Why?
|
| Survival Rate | 38 | 2019 | 797 | 3.450 |
Why?
|
| Renal Insufficiency, Chronic | 24 | 2022 | 272 | 3.370 |
Why?
|
| Smoking | 18 | 2019 | 441 | 3.250 |
Why?
|
| Blood Pressure | 32 | 2023 | 813 | 3.230 |
Why?
|
| Coronary Disease | 17 | 2021 | 202 | 3.180 |
Why?
|
| Cross-Sectional Studies | 55 | 2023 | 1389 | 3.140 |
Why?
|
| Bundle-Branch Block | 11 | 2023 | 19 | 3.010 |
Why?
|
| Diagnosis, Computer-Assisted | 7 | 2019 | 47 | 2.920 |
Why?
|
| Atrial Function, Left | 8 | 2022 | 18 | 2.910 |
Why?
|
| Time Factors | 55 | 2021 | 2014 | 2.870 |
Why?
|
| Sex Factors | 42 | 2021 | 633 | 2.810 |
Why?
|
| Forecasting | 9 | 2019 | 133 | 2.720 |
Why?
|
| Multivariate Analysis | 35 | 2019 | 638 | 2.710 |
Why?
|
| Adult | 99 | 2023 | 8528 | 2.710 |
Why?
|
| African Continental Ancestry Group | 23 | 2018 | 350 | 2.640 |
Why?
|
| Hispanic Americans | 21 | 2020 | 903 | 2.600 |
Why?
|
| Population Surveillance | 10 | 2018 | 119 | 2.520 |
Why?
|
| Genome-Wide Association Study | 37 | 2023 | 546 | 2.520 |
Why?
|
| Echocardiography | 12 | 2022 | 141 | 2.420 |
Why?
|
| Stroke Volume | 9 | 2021 | 282 | 2.350 |
Why?
|
| Ventricular Premature Complexes | 10 | 2021 | 13 | 2.320 |
Why?
|
| Cotinine | 5 | 2022 | 45 | 2.290 |
Why?
|
| Comorbidity | 33 | 2022 | 548 | 2.240 |
Why?
|
| Sex Distribution | 21 | 2019 | 188 | 2.210 |
Why?
|
| Brugada Syndrome | 11 | 2017 | 17 | 2.120 |
Why?
|
| Electrocardiography, Ambulatory | 16 | 2023 | 21 | 2.090 |
Why?
|
| Health Status Disparities | 9 | 2016 | 115 | 2.000 |
Why?
|
| Obesity | 17 | 2021 | 1081 | 1.930 |
Why?
|
| Odds Ratio | 25 | 2021 | 448 | 1.900 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2022 | 180 | 1.890 |
Why?
|
| Retrospective Studies | 35 | 2022 | 3144 | 1.850 |
Why?
|
| Reproducibility of Results | 27 | 2022 | 727 | 1.810 |
Why?
|
| Diet | 4 | 2023 | 356 | 1.780 |
Why?
|
| Logistic Models | 20 | 2021 | 729 | 1.710 |
Why?
|
| Ventricular Function, Left | 8 | 2021 | 198 | 1.670 |
Why?
|
| Heart Block | 4 | 2022 | 9 | 1.660 |
Why?
|
| Longitudinal Studies | 33 | 2021 | 727 | 1.650 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2020 | 1389 | 1.640 |
Why?
|
| Asian Americans | 9 | 2020 | 98 | 1.630 |
Why?
|
| Heart Ventricles | 9 | 2021 | 108 | 1.620 |
Why?
|
| Heart | 8 | 2023 | 165 | 1.590 |
Why?
|
| Exercise | 9 | 2024 | 610 | 1.560 |
Why?
|
| Age Factors | 35 | 2021 | 1120 | 1.550 |
Why?
|
| Diabetes Mellitus | 15 | 2024 | 376 | 1.540 |
Why?
|
| Sleep Apnea Syndromes | 4 | 2020 | 28 | 1.540 |
Why?
|
| Anticoagulants | 9 | 2024 | 122 | 1.530 |
Why?
|
| Sensitivity and Specificity | 22 | 2021 | 533 | 1.520 |
Why?
|
| Genetic Loci | 16 | 2020 | 147 | 1.490 |
Why?
|
| Magnetic Resonance Imaging, Cine | 7 | 2020 | 64 | 1.480 |
Why?
|
| Action Potentials | 11 | 2021 | 175 | 1.410 |
Why?
|
| Residence Characteristics | 11 | 2019 | 182 | 1.410 |
Why?
|
| Bilirubin | 2 | 2020 | 22 | 1.410 |
Why?
|
| Signal Processing, Computer-Assisted | 7 | 2018 | 33 | 1.410 |
Why?
|
| Vitamin D Deficiency | 3 | 2019 | 91 | 1.390 |
Why?
|
| Survival Analysis | 7 | 2018 | 440 | 1.390 |
Why?
|
| Cardiomyopathies | 7 | 2023 | 50 | 1.380 |
Why?
|
| Spironolactone | 3 | 2017 | 11 | 1.320 |
Why?
|
| Myocardial Ischemia | 4 | 2019 | 85 | 1.320 |
Why?
|
| HIV Infections | 9 | 2021 | 373 | 1.320 |
Why?
|
| Dementia | 9 | 2022 | 237 | 1.300 |
Why?
|
| Polymorphism, Single Nucleotide | 29 | 2019 | 1080 | 1.280 |
Why?
|
| Pacemaker, Artificial | 3 | 2019 | 17 | 1.250 |
Why?
|
| Thromboembolism | 4 | 2020 | 30 | 1.250 |
Why?
|
| Chi-Square Distribution | 14 | 2017 | 294 | 1.240 |
Why?
|
| Linear Models | 15 | 2019 | 427 | 1.240 |
Why?
|
| Mass Screening | 7 | 2018 | 228 | 1.200 |
Why?
|
| Myocardium | 7 | 2019 | 170 | 1.200 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2023 | 1225 | 1.170 |
Why?
|
| Age Distribution | 13 | 2019 | 199 | 1.160 |
Why?
|
| Vitamin D | 6 | 2023 | 175 | 1.140 |
Why?
|
| Risk | 14 | 2020 | 293 | 1.140 |
Why?
|
| Blood Glucose | 10 | 2022 | 469 | 1.130 |
Why?
|
| Natriuretic Peptide, Brain | 12 | 2022 | 59 | 1.130 |
Why?
|
| Algorithms | 5 | 2014 | 468 | 1.130 |
Why?
|
| Developing Countries | 4 | 2017 | 43 | 1.120 |
Why?
|
| Diabetes Complications | 8 | 2020 | 171 | 1.120 |
Why?
|
| Stress, Psychological | 3 | 2017 | 210 | 1.120 |
Why?
|
| Blood Pressure Determination | 7 | 2023 | 95 | 1.110 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2016 | 10 | 1.100 |
Why?
|
| Mortality | 10 | 2017 | 114 | 1.090 |
Why?
|
| Mitral Valve | 2 | 2018 | 28 | 1.090 |
Why?
|
| Health Status | 5 | 2020 | 373 | 1.080 |
Why?
|
| C-Reactive Protein | 10 | 2019 | 235 | 1.070 |
Why?
|
| Atrial Flutter | 5 | 2018 | 12 | 1.060 |
Why?
|
| American Heart Association | 6 | 2019 | 84 | 1.050 |
Why?
|
| Calcinosis | 2 | 2018 | 143 | 1.040 |
Why?
|
| Aging | 8 | 2023 | 891 | 1.040 |
Why?
|
| Pattern Recognition, Automated | 2 | 2016 | 34 | 1.030 |
Why?
|
| Troponin T | 10 | 2023 | 64 | 1.010 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2017 | 137 | 0.980 |
Why?
|
| Ventricular Remodeling | 3 | 2019 | 53 | 0.960 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2021 | 840 | 0.950 |
Why?
|
| Interleukin-6 | 6 | 2021 | 225 | 0.950 |
Why?
|
| Uric Acid | 3 | 2021 | 24 | 0.950 |
Why?
|
| Atrioventricular Block | 3 | 2023 | 4 | 0.950 |
Why?
|
| Hospitalization | 8 | 2020 | 423 | 0.950 |
Why?
|
| Postural Balance | 2 | 2016 | 163 | 0.940 |
Why?
|
| Pesticides | 2 | 2016 | 188 | 0.900 |
Why?
|
| Rest | 5 | 2019 | 50 | 0.900 |
Why?
|
| Occupational Exposure | 2 | 2016 | 223 | 0.890 |
Why?
|
| Double-Blind Method | 9 | 2024 | 507 | 0.880 |
Why?
|
| Socioeconomic Factors | 10 | 2022 | 396 | 0.880 |
Why?
|
| Emigrants and Immigrants | 2 | 2016 | 234 | 0.870 |
Why?
|
| Peptide Fragments | 11 | 2021 | 423 | 0.870 |
Why?
|
| Transients and Migrants | 2 | 2016 | 280 | 0.860 |
Why?
|
| Sex Characteristics | 5 | 2021 | 167 | 0.860 |
Why?
|
| Body Mass Index | 16 | 2022 | 876 | 0.840 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 121 | 0.820 |
Why?
|
| Genetic Variation | 8 | 2021 | 251 | 0.810 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2019 | 6 | 0.790 |
Why?
|
| Confidence Intervals | 10 | 2020 | 141 | 0.790 |
Why?
|
| Disease Progression | 10 | 2019 | 574 | 0.780 |
Why?
|
| Respiration | 2 | 2018 | 26 | 0.770 |
Why?
|
| Women's Health | 5 | 2018 | 226 | 0.760 |
Why?
|
| Treatment Outcome | 16 | 2020 | 3128 | 0.760 |
Why?
|
| North Carolina | 9 | 2019 | 1430 | 0.740 |
Why?
|
| Fasting | 2 | 2020 | 93 | 0.740 |
Why?
|
| Severity of Illness Index | 11 | 2020 | 864 | 0.730 |
Why?
|
| Aspirin | 6 | 2024 | 66 | 0.710 |
Why?
|
| Hypoglycemia | 1 | 2020 | 41 | 0.710 |
Why?
|
| Case-Control Studies | 12 | 2021 | 861 | 0.700 |
Why?
|
| Mexican Americans | 2 | 2017 | 59 | 0.700 |
Why?
|
| Income | 4 | 2018 | 52 | 0.700 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2017 | 28 | 0.700 |
Why?
|
| Patient Care Planning | 1 | 2020 | 54 | 0.690 |
Why?
|
| Cardiac Electrophysiology | 2 | 2018 | 3 | 0.680 |
Why?
|
| Young Adult | 26 | 2021 | 2431 | 0.680 |
Why?
|
| Cardiomegaly | 2 | 2016 | 30 | 0.680 |
Why?
|
| Marital Status | 1 | 2019 | 20 | 0.680 |
Why?
|
| Electrodes | 3 | 2014 | 17 | 0.670 |
Why?
|
| Inflammation | 7 | 2023 | 511 | 0.670 |
Why?
|
| Social Class | 6 | 2023 | 78 | 0.670 |
Why?
|
| Albuminuria | 7 | 2023 | 178 | 0.660 |
Why?
|
| Registries | 3 | 2020 | 280 | 0.650 |
Why?
|
| Primary Prevention | 5 | 2017 | 52 | 0.650 |
Why?
|
| Sleep | 3 | 2020 | 88 | 0.650 |
Why?
|
| Anti-Retroviral Agents | 3 | 2018 | 21 | 0.650 |
Why?
|
| Autonomic Nervous System | 4 | 2020 | 42 | 0.640 |
Why?
|
| Lung | 2 | 2017 | 237 | 0.630 |
Why?
|
| Artifacts | 2 | 2008 | 38 | 0.630 |
Why?
|
| Kidney Failure, Chronic | 5 | 2016 | 522 | 0.630 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 13 | 0.620 |
Why?
|
| Independent Living | 7 | 2019 | 85 | 0.620 |
Why?
|
| Hospitals, Rural | 1 | 2017 | 11 | 0.610 |
Why?
|
| Happiness | 1 | 2017 | 3 | 0.610 |
Why?
|
| Reference Values | 5 | 2016 | 225 | 0.610 |
Why?
|
| Unemployment | 1 | 2017 | 4 | 0.610 |
Why?
|
| Life Expectancy | 1 | 2017 | 16 | 0.600 |
Why?
|
| Glomerular Filtration Rate | 11 | 2021 | 289 | 0.600 |
Why?
|
| Echocardiography, Doppler | 1 | 2017 | 39 | 0.600 |
Why?
|
| Neoplasms | 4 | 2018 | 628 | 0.600 |
Why?
|
| Health Resources | 1 | 2017 | 33 | 0.580 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 2 | 0.570 |
Why?
|
| Paper | 1 | 2016 | 2 | 0.570 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 101 | 0.560 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 25 | 0.560 |
Why?
|
| Life Style | 5 | 2022 | 369 | 0.560 |
Why?
|
| Coronary Vessels | 2 | 2014 | 151 | 0.560 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2022 | 85 | 0.540 |
Why?
|
| Awareness | 1 | 2016 | 29 | 0.540 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2015 | 17 | 0.530 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 328 | 0.520 |
Why?
|
| Electronic Health Records | 1 | 2016 | 121 | 0.520 |
Why?
|
| Microvessels | 1 | 2015 | 23 | 0.520 |
Why?
|
| Retinal Vessels | 1 | 2015 | 18 | 0.510 |
Why?
|
| Cerebrovascular Trauma | 1 | 2015 | 1 | 0.510 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 12 | 0.510 |
Why?
|
| Postmenopause | 6 | 2018 | 398 | 0.500 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 48 | 0.500 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 25 | 0.490 |
Why?
|
| Cardiovascular Agents | 2 | 2013 | 18 | 0.490 |
Why?
|
| Brachial Artery | 1 | 2014 | 66 | 0.480 |
Why?
|
| Autonomic Nervous System Diseases | 3 | 2021 | 9 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 471 | 0.480 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 494 | 0.480 |
Why?
|
| Vasodilation | 1 | 2014 | 87 | 0.480 |
Why?
|
| Defibrillators, Implantable | 2 | 2019 | 17 | 0.480 |
Why?
|
| Blood Coagulation | 1 | 2014 | 13 | 0.470 |
Why?
|
| Ultrasonography | 7 | 2015 | 350 | 0.460 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2019 | 48 | 0.460 |
Why?
|
| Ventricular Dysfunction | 2 | 2011 | 4 | 0.450 |
Why?
|
| Accidental Falls | 1 | 2015 | 211 | 0.450 |
Why?
|
| Atrioventricular Node | 4 | 2018 | 5 | 0.440 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 62 | 0.440 |
Why?
|
| Decision Support Techniques | 3 | 2021 | 104 | 0.440 |
Why?
|
| Software | 1 | 2013 | 110 | 0.430 |
Why?
|
| Electrophysiological Phenomena | 3 | 2018 | 28 | 0.420 |
Why?
|
| Particulate Matter | 3 | 2017 | 30 | 0.420 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 248 | 0.420 |
Why?
|
| Geography | 6 | 2017 | 34 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2018 | 875 | 0.410 |
Why?
|
| Recurrence | 6 | 2020 | 235 | 0.410 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 299 | 0.410 |
Why?
|
| Quantitative Trait Loci | 8 | 2020 | 141 | 0.410 |
Why?
|
| Quality of Life | 1 | 2017 | 833 | 0.400 |
Why?
|
| Chlorthalidone | 6 | 2017 | 13 | 0.400 |
Why?
|
| Insulin Resistance | 4 | 2020 | 451 | 0.400 |
Why?
|
| Lisinopril | 6 | 2017 | 28 | 0.400 |
Why?
|
| Alcohol Drinking | 5 | 2018 | 248 | 0.400 |
Why?
|
| Tachycardia, Supraventricular | 3 | 2021 | 5 | 0.390 |
Why?
|
| Pyrazoles | 2 | 2024 | 65 | 0.390 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 14 | 0.390 |
Why?
|
| Health Surveys | 5 | 2020 | 192 | 0.380 |
Why?
|
| World Health Organization | 1 | 2011 | 15 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2020 | 137 | 0.380 |
Why?
|
| Fibroblast Growth Factors | 3 | 2018 | 34 | 0.380 |
Why?
|
| Dyslipidemias | 3 | 2016 | 54 | 0.380 |
Why?
|
| HIV-1 | 1 | 2011 | 45 | 0.380 |
Why?
|
| Pericardium | 2 | 2010 | 50 | 0.370 |
Why?
|
| Depression | 3 | 2019 | 386 | 0.370 |
Why?
|
| Systole | 4 | 2018 | 88 | 0.370 |
Why?
|
| HIV | 3 | 2017 | 22 | 0.370 |
Why?
|
| Databases, Factual | 6 | 2017 | 333 | 0.360 |
Why?
|
| Referral and Consultation | 1 | 2011 | 113 | 0.360 |
Why?
|
| Adipose Tissue | 2 | 2010 | 332 | 0.360 |
Why?
|
| Anti-HIV Agents | 3 | 2017 | 54 | 0.360 |
Why?
|
| Southeastern United States | 5 | 2017 | 72 | 0.360 |
Why?
|
| Tunica Media | 1 | 2010 | 29 | 0.360 |
Why?
|
| Coronary Restenosis | 1 | 2009 | 13 | 0.350 |
Why?
|
| Tunica Intima | 1 | 2010 | 59 | 0.350 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 37 | 0.350 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 29 | 0.350 |
Why?
|
| Diuretics | 3 | 2017 | 22 | 0.350 |
Why?
|
| Vitamins | 2 | 2018 | 61 | 0.340 |
Why?
|
| Animals | 10 | 2021 | 7339 | 0.340 |
Why?
|
| Ischemic Attack, Transient | 3 | 2022 | 46 | 0.340 |
Why?
|
| Folic Acid | 2 | 2010 | 12 | 0.340 |
Why?
|
| Research Design | 3 | 2019 | 289 | 0.340 |
Why?
|
| Hyperlipidemias | 2 | 2021 | 52 | 0.340 |
Why?
|
| Testosterone | 3 | 2019 | 49 | 0.340 |
Why?
|
| Magnesium | 3 | 2023 | 22 | 0.330 |
Why?
|
| Ventricular Fibrillation | 1 | 2009 | 4 | 0.330 |
Why?
|
| Vascular Diseases | 2 | 2016 | 62 | 0.330 |
Why?
|
| Phenotype | 7 | 2019 | 633 | 0.330 |
Why?
|
| Fibrinogen | 4 | 2019 | 42 | 0.330 |
Why?
|
| Affect | 2 | 2019 | 64 | 0.330 |
Why?
|
| Exercise Test | 3 | 2019 | 194 | 0.330 |
Why?
|
| Echocardiography, Stress | 1 | 2008 | 22 | 0.330 |
Why?
|
| Triglycerides | 4 | 2020 | 218 | 0.320 |
Why?
|
| Adolescent | 16 | 2021 | 3284 | 0.320 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 53 | 0.320 |
Why?
|
| Electric Wiring | 1 | 2008 | 1 | 0.320 |
Why?
|
| Thorax | 1 | 2008 | 27 | 0.320 |
Why?
|
| Heart Defects, Congenital | 1 | 2008 | 28 | 0.320 |
Why?
|
| Genotype | 10 | 2018 | 735 | 0.320 |
Why?
|
| Homocysteine | 1 | 2008 | 15 | 0.320 |
Why?
|
| Patient Rights | 1 | 2008 | 14 | 0.310 |
Why?
|
| Pericarditis | 1 | 2008 | 6 | 0.310 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 42 | 0.310 |
Why?
|
| Calcium | 4 | 2023 | 302 | 0.310 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 71 | 0.310 |
Why?
|
| Amlodipine | 5 | 2017 | 14 | 0.300 |
Why?
|
| Organ Size | 5 | 2022 | 196 | 0.300 |
Why?
|
| Intracranial Embolism | 2 | 2018 | 13 | 0.300 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 35 | 0.290 |
Why?
|
| Kidney Diseases | 4 | 2016 | 239 | 0.290 |
Why?
|
| Diabetic Retinopathy | 2 | 2018 | 64 | 0.290 |
Why?
|
| Brain | 3 | 2019 | 933 | 0.280 |
Why?
|
| Feasibility Studies | 3 | 2022 | 270 | 0.280 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2022 | 6 | 0.280 |
Why?
|
| Connexin 43 | 2 | 2018 | 4 | 0.270 |
Why?
|
| Ischemia | 2 | 2018 | 94 | 0.270 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 153 | 0.270 |
Why?
|
| Obesity, Abdominal | 3 | 2022 | 23 | 0.260 |
Why?
|
| Anxiety | 2 | 2019 | 161 | 0.260 |
Why?
|
| Cognition Disorders | 3 | 2018 | 391 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 376 | 0.260 |
Why?
|
| Ankle Brachial Index | 2 | 2015 | 38 | 0.250 |
Why?
|
| Survivors | 2 | 2017 | 149 | 0.250 |
Why?
|
| Diabetic Angiopathies | 3 | 2021 | 137 | 0.250 |
Why?
|
| Cognition | 3 | 2018 | 529 | 0.250 |
Why?
|
| Waist Circumference | 6 | 2022 | 90 | 0.250 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 363 | 0.240 |
Why?
|
| Phosphorus | 3 | 2013 | 11 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 643 | 0.240 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2017 | 135 | 0.230 |
Why?
|
| Warfarin | 2 | 2016 | 30 | 0.230 |
Why?
|
| Morbidity | 4 | 2018 | 92 | 0.230 |
Why?
|
| Losartan | 1 | 2023 | 70 | 0.230 |
Why?
|
| Chagas Disease | 1 | 2023 | 7 | 0.230 |
Why?
|
| Tachycardia, Ventricular | 2 | 2020 | 14 | 0.220 |
Why?
|
| Pyridones | 2 | 2024 | 10 | 0.220 |
Why?
|
| Cholesterol | 2 | 2017 | 239 | 0.220 |
Why?
|
| Medicare | 3 | 2019 | 189 | 0.220 |
Why?
|
| Infant | 3 | 2018 | 976 | 0.210 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 148 | 0.210 |
Why?
|
| Motor Activity | 2 | 2015 | 315 | 0.210 |
Why?
|
| Atrial Appendage | 1 | 2022 | 9 | 0.210 |
Why?
|
| Health Status Indicators | 2 | 2020 | 67 | 0.210 |
Why?
|
| Bayes Theorem | 2 | 2019 | 70 | 0.200 |
Why?
|
| Meta-Analysis as Topic | 6 | 2012 | 39 | 0.200 |
Why?
|
| Hydrochlorothiazide | 2 | 2011 | 3 | 0.200 |
Why?
|
| Likelihood Functions | 1 | 2021 | 40 | 0.200 |
Why?
|
| Zebrafish | 1 | 2021 | 24 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 548 | 0.200 |
Why?
|
| Demography | 3 | 2017 | 105 | 0.200 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 23 | 0.200 |
Why?
|
| Heterozygote | 1 | 2021 | 53 | 0.200 |
Why?
|
| Decision Trees | 2 | 2019 | 23 | 0.200 |
Why?
|
| Hypoglycemic Agents | 3 | 2022 | 177 | 0.200 |
Why?
|
| Child | 7 | 2014 | 2234 | 0.190 |
Why?
|
| Sinoatrial Node | 1 | 2020 | 2 | 0.190 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2019 | 6 | 0.190 |
Why?
|
| Epistasis, Genetic | 2 | 2017 | 44 | 0.190 |
Why?
|
| Atrial Function, Right | 1 | 2020 | 1 | 0.190 |
Why?
|
| Electrolytes | 1 | 2020 | 9 | 0.180 |
Why?
|
| Diastole | 2 | 2017 | 91 | 0.180 |
Why?
|
| Aftercare | 1 | 2020 | 29 | 0.180 |
Why?
|
| Reference Standards | 1 | 2019 | 30 | 0.180 |
Why?
|
| Matched-Pair Analysis | 2 | 2010 | 11 | 0.180 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 119 | 0.180 |
Why?
|
| Coronary Circulation | 2 | 2017 | 30 | 0.170 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 1 | 0.170 |
Why?
|
| rho-Associated Kinases | 1 | 2019 | 7 | 0.170 |
Why?
|
| Genomics | 2 | 2017 | 82 | 0.170 |
Why?
|
| Metabolomics | 2 | 2019 | 46 | 0.170 |
Why?
|
| Potassium | 1 | 2019 | 37 | 0.170 |
Why?
|
| Glycocholic Acid | 1 | 2019 | 1 | 0.170 |
Why?
|
| Uridine | 1 | 2019 | 3 | 0.170 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 6 | 0.170 |
Why?
|
| Pyrrolidinones | 1 | 2019 | 5 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 161 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2019 | 30 | 0.170 |
Why?
|
| Alleles | 5 | 2019 | 252 | 0.170 |
Why?
|
| Health Behavior | 2 | 2018 | 217 | 0.170 |
Why?
|
| Migraine with Aura | 1 | 2018 | 2 | 0.170 |
Why?
|
| Muscle Proteins | 3 | 2017 | 57 | 0.170 |
Why?
|
| B-Cell Activating Factor | 1 | 2018 | 2 | 0.170 |
Why?
|
| Intracranial Thrombosis | 1 | 2018 | 8 | 0.170 |
Why?
|
| Calcium, Dietary | 1 | 2018 | 24 | 0.170 |
Why?
|
| Models, Cardiovascular | 2 | 2016 | 27 | 0.170 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 38 | 0.160 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 41 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 71 | 0.160 |
Why?
|
| Environmental Exposure | 2 | 2017 | 87 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 282 | 0.160 |
Why?
|
| Atrial Function | 1 | 2018 | 1 | 0.160 |
Why?
|
| Statistics as Topic | 2 | 2017 | 107 | 0.160 |
Why?
|
| Macular Edema | 1 | 2018 | 15 | 0.160 |
Why?
|
| Public Health | 1 | 2019 | 76 | 0.160 |
Why?
|
| Cardiology | 2 | 2016 | 83 | 0.160 |
Why?
|
| Platelet Activation | 1 | 2017 | 12 | 0.160 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 1 | 0.160 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2017 | 5 | 0.150 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2017 | 9 | 0.150 |
Why?
|
| Visual Acuity | 1 | 2018 | 69 | 0.150 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2014 | 9 | 0.150 |
Why?
|
| Myocardial Contraction | 1 | 2018 | 55 | 0.150 |
Why?
|
| Body Size | 1 | 2017 | 31 | 0.150 |
Why?
|
| Developed Countries | 1 | 2017 | 4 | 0.150 |
Why?
|
| Ecosystem | 1 | 2017 | 6 | 0.150 |
Why?
|
| Secondary Prevention | 2 | 2020 | 59 | 0.150 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2017 | 10 | 0.150 |
Why?
|
| Galectin 3 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Asian Continental Ancestry Group | 3 | 2012 | 110 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 96 | 0.150 |
Why?
|
| Internationality | 1 | 2017 | 21 | 0.150 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 54 | 0.150 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 5 | 0.150 |
Why?
|
| Kenya | 1 | 2017 | 10 | 0.150 |
Why?
|
| Pulmonary Emphysema | 1 | 2016 | 8 | 0.150 |
Why?
|
| Viral Load | 2 | 2021 | 67 | 0.140 |
Why?
|
| Database Management Systems | 1 | 2016 | 11 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2015 | 275 | 0.140 |
Why?
|
| Air Pollution | 1 | 2016 | 17 | 0.140 |
Why?
|
| Air Pollutants | 1 | 2016 | 20 | 0.140 |
Why?
|
| Coronary Vasospasm | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2017 | 190 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 33 | 0.140 |
Why?
|
| Calcium Channel Blockers | 1 | 2016 | 49 | 0.140 |
Why?
|
| Digoxin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Causality | 1 | 2016 | 39 | 0.140 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2016 | 2 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 484 | 0.140 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 35 | 0.140 |
Why?
|
| Sodium | 1 | 2016 | 37 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 177 | 0.140 |
Why?
|
| Sodium, Dietary | 1 | 2016 | 24 | 0.140 |
Why?
|
| Bradycardia | 1 | 2016 | 15 | 0.140 |
Why?
|
| Cardiotoxins | 1 | 2016 | 6 | 0.140 |
Why?
|
| Chest Pain | 1 | 2018 | 180 | 0.130 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 6 | 0.130 |
Why?
|
| Hemostasis | 1 | 2015 | 5 | 0.130 |
Why?
|
| Single-Blind Method | 3 | 2014 | 174 | 0.130 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 110 | 0.130 |
Why?
|
| Brain Infarction | 1 | 2015 | 10 | 0.130 |
Why?
|
| Coronary Angiography | 1 | 2015 | 139 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 63 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 18 | 0.130 |
Why?
|
| Lipids | 2 | 2016 | 215 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2015 | 92 | 0.120 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2014 | 13 | 0.120 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 12 | 0.120 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2021 | 8 | 0.120 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 59 | 0.120 |
Why?
|
| Physical Fitness | 1 | 2015 | 120 | 0.120 |
Why?
|
| Glycemic Index | 1 | 2014 | 14 | 0.120 |
Why?
|
| ROC Curve | 1 | 2014 | 149 | 0.120 |
Why?
|
| Infant, Low Birth Weight | 1 | 2014 | 9 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 28 | 0.120 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 44 | 0.120 |
Why?
|
| Child, Preschool | 4 | 2012 | 1172 | 0.120 |
Why?
|
| Sodium Channels | 2 | 2011 | 13 | 0.120 |
Why?
|
| Aldosterone | 1 | 2014 | 28 | 0.120 |
Why?
|
| Birth Weight | 1 | 2014 | 39 | 0.120 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2013 | 4 | 0.120 |
Why?
|
| Epidemiologic Studies | 2 | 2016 | 20 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2011 | 86 | 0.120 |
Why?
|
| Hypotension, Orthostatic | 1 | 2013 | 10 | 0.120 |
Why?
|
| Aorta, Thoracic | 1 | 2014 | 72 | 0.120 |
Why?
|
| Body Surface Potential Mapping | 1 | 2013 | 12 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 145 | 0.120 |
Why?
|
| Weight Gain | 1 | 2014 | 109 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 105 | 0.110 |
Why?
|
| Insulin | 3 | 2022 | 347 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 31 | 0.110 |
Why?
|
| Linkage Disequilibrium | 3 | 2018 | 192 | 0.110 |
Why?
|
| Kidney | 1 | 2017 | 488 | 0.110 |
Why?
|
| Genealogy and Heraldry | 1 | 2012 | 1 | 0.110 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 50 | 0.110 |
Why?
|
| Cholesterol, HDL | 4 | 2015 | 167 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2018 | 155 | 0.110 |
Why?
|
| Fish Products | 1 | 2012 | 1 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2013 | 54 | 0.110 |
Why?
|
| Factor VIII | 3 | 2021 | 22 | 0.110 |
Why?
|
| Models, Biological | 1 | 2014 | 375 | 0.110 |
Why?
|
| Educational Status | 3 | 2018 | 165 | 0.100 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 13 | 0.100 |
Why?
|
| Risk Adjustment | 1 | 2011 | 27 | 0.100 |
Why?
|
| Sri Lanka | 1 | 2011 | 3 | 0.100 |
Why?
|
| Weight Loss | 1 | 2014 | 416 | 0.100 |
Why?
|
| Simvastatin | 1 | 2011 | 25 | 0.100 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 17 | 0.090 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 20 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2010 | 22 | 0.090 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 4 | 0.090 |
Why?
|
| Fibrosis | 2 | 2023 | 104 | 0.090 |
Why?
|
| Canada | 2 | 2024 | 50 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2023 | 172 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2012 | 237 | 0.090 |
Why?
|
| Cystatin C | 2 | 2021 | 28 | 0.090 |
Why?
|
| Mice | 4 | 2019 | 2387 | 0.090 |
Why?
|
| Random Allocation | 2 | 2022 | 214 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 163 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2011 | 144 | 0.080 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2019 | 23 | 0.080 |
Why?
|
| Rheumatic Heart Disease | 1 | 2008 | 2 | 0.080 |
Why?
|
| Guatemala | 1 | 2008 | 7 | 0.080 |
Why?
|
| Malawi | 1 | 2008 | 19 | 0.080 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2023 | 17 | 0.080 |
Why?
|
| Dobutamine | 1 | 2008 | 43 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 50 | 0.080 |
Why?
|
| Quality Control | 1 | 2008 | 38 | 0.080 |
Why?
|
| Adiposity | 1 | 2010 | 192 | 0.080 |
Why?
|
| Food, Fortified | 1 | 2008 | 5 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2008 | 42 | 0.080 |
Why?
|
| Placebo Effect | 1 | 2007 | 14 | 0.080 |
Why?
|
| Research Personnel | 1 | 2007 | 13 | 0.080 |
Why?
|
| Gene Expression | 2 | 2020 | 334 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 233 | 0.080 |
Why?
|
| Wisconsin | 2 | 2018 | 18 | 0.080 |
Why?
|
| Probability | 1 | 2008 | 151 | 0.080 |
Why?
|
| Culture | 1 | 2007 | 38 | 0.080 |
Why?
|
| Polysomnography | 2 | 2019 | 33 | 0.080 |
Why?
|
| Patients | 1 | 2007 | 46 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2014 | 605 | 0.070 |
Why?
|
| Potassium Channels | 2 | 2017 | 20 | 0.070 |
Why?
|
| Acute Disease | 1 | 2008 | 239 | 0.070 |
Why?
|
| Mutation | 1 | 2009 | 475 | 0.070 |
Why?
|
| Pediatrics | 1 | 2008 | 132 | 0.070 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 111 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2017 | 225 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 209 | 0.070 |
Why?
|
| Netherlands | 2 | 2019 | 21 | 0.070 |
Why?
|
| Creatinine | 2 | 2017 | 175 | 0.070 |
Why?
|
| Spirometry | 2 | 2016 | 33 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2016 | 113 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2017 | 10 | 0.060 |
Why?
|
| T-Box Domain Proteins | 2 | 2017 | 12 | 0.060 |
Why?
|
| Cicatrix | 2 | 2016 | 36 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2024 | 32 | 0.060 |
Why?
|
| Growth Differentiation Factors | 1 | 2023 | 2 | 0.060 |
Why?
|
| Gadolinium | 1 | 2023 | 19 | 0.060 |
Why?
|
| Cholecalciferol | 1 | 2023 | 23 | 0.060 |
Why?
|
| Homeostasis | 2 | 2016 | 127 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2024 | 94 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 81 | 0.060 |
Why?
|
| Contrast Media | 1 | 2023 | 124 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2016 | 250 | 0.050 |
Why?
|
| Virulence | 1 | 2022 | 21 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 53 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2022 | 24 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2022 | 90 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 24 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 70 | 0.050 |
Why?
|
| Minnesota | 2 | 2011 | 18 | 0.050 |
Why?
|
| Mississippi | 1 | 2021 | 24 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 165 | 0.050 |
Why?
|
| Myocytes, Cardiac | 2 | 2011 | 87 | 0.050 |
Why?
|
| Galectins | 1 | 2020 | 6 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2020 | 18 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 21 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2011 | 372 | 0.040 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2019 | 35 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2019 | 183 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2018 | 10 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2018 | 19 | 0.040 |
Why?
|
| Vectorcardiography | 1 | 2018 | 1 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2018 | 48 | 0.040 |
Why?
|
| Ohio | 1 | 2018 | 55 | 0.040 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2018 | 10 | 0.040 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2017 | 9 | 0.040 |
Why?
|
| Antiporters | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 456 | 0.040 |
Why?
|
| Brazil | 1 | 2017 | 13 | 0.040 |
Why?
|
| Oregon | 1 | 2017 | 7 | 0.040 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2017 | 27 | 0.040 |
Why?
|
| Metolazone | 1 | 2017 | 1 | 0.040 |
Why?
|
| Hydroxyzine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Amiodarone | 1 | 2017 | 3 | 0.040 |
Why?
|
| Caveolin 2 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Furosemide | 1 | 2017 | 6 | 0.040 |
Why?
|
| Citalopram | 1 | 2017 | 5 | 0.040 |
Why?
|
| Histamine H1 Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2017 | 17 | 0.040 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2017 | 10 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 11 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2017 | 62 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 23 | 0.040 |
Why?
|
| Caveolin 1 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Mercaptoethanol | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2017 | 8 | 0.040 |
Why?
|
| RGS Proteins | 1 | 2017 | 18 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 143 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2016 | 6 | 0.040 |
Why?
|
| Tennessee | 1 | 2017 | 97 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 55 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 321 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2016 | 44 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 14 | 0.040 |
Why?
|
| Particle Size | 1 | 2016 | 43 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 34 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2018 | 174 | 0.040 |
Why?
|
| Selection Bias | 1 | 2016 | 13 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 247 | 0.040 |
Why?
|
| Shab Potassium Channels | 1 | 2016 | 2 | 0.030 |
Why?
|
| Shal Potassium Channels | 1 | 2016 | 7 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 275 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 38 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2016 | 9 | 0.030 |
Why?
|
| Anthropometry | 1 | 2016 | 82 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 96 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 381 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 68 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2016 | 53 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 39 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 66 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 100 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 55 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2016 | 51 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2016 | 76 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 39 | 0.030 |
Why?
|
| Denmark | 1 | 2014 | 3 | 0.030 |
Why?
|
| China | 1 | 2014 | 44 | 0.030 |
Why?
|
| Israel | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sudden Infant Death | 1 | 2014 | 5 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 15 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 210 | 0.030 |
Why?
|
| Death, Sudden | 1 | 2014 | 8 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2014 | 47 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 440 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 78 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 221 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 152 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 139 | 0.030 |
Why?
|
| Athletes | 1 | 2014 | 65 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 43 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 164 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 53 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 261 | 0.030 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Iceland | 1 | 2013 | 1 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Military Personnel | 1 | 2014 | 86 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2013 | 17 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2013 | 47 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2012 | 50 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2012 | 27 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2012 | 21 | 0.030 |
Why?
|
| Phospholipids | 1 | 2012 | 27 | 0.030 |
Why?
|
| Genome, Human | 1 | 2012 | 129 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 3 | 0.030 |
Why?
|
| Glucuronidase | 1 | 2011 | 9 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 17 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 21 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 257 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 226 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 110 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2010 | 9 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 249 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 455 | 0.020 |
Why?
|
| Protein C | 1 | 2010 | 2 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2010 | 6 | 0.020 |
Why?
|
| Factor VII | 1 | 2010 | 5 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hematinics | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 62 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2010 | 111 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 86 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 425 | 0.020 |
Why?
|
| Introns | 1 | 2010 | 40 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 161 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 525 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 249 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 141 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 178 | 0.020 |
Why?
|
| Minority Health | 1 | 2009 | 7 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2009 | 23 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 713 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2011 | 674 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 984 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2007 | 19 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1609 | 0.020 |
Why?
|